A Clinical Evaluation of Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer: Guiding Principles for Treatment Selection and Perspectives on Research

• Published in: OncoTargets and therapy 2020-01, Vol.13, p.13247-13263
• Main Authors: Laccetti, Andrew L, Morris, Michael J, Kantoff, Philip W
• Format: Article
• Language: English
• Subjects: Androgen receptors; Androgens; Cancer therapies; Castration; Chemotherapy; Cognitive ability; Ligands; Metastases; Metastasis; Prostate cancer; Review; Toxicity; Treatment resistance
• ISSN: 1178-6930; 1178-6930
• DOI: 10.2147/OTT.S242921

Enzalutamide was the first novel androgen receptor signaling inhibitor to demonstrate an overall survival benefit in non-metastatic and metastatic castration-sensitive prostate cancer (CSPC). It has emerged as one of the most commonly prescribed oral prostate cancer therapies (ARSI) by medical oncologists and urologists. Amongst a panoply of treatment options for metastatic CSPC, safe and effective utilization of enzalutamide dictates a detailed understanding of alternative therapy options and competing toxicity profiles. Ongoing research supports the potential for expanded enzalutamide use in earlier disease states, in combination with other systemic agents and as monotherapy (without androgen deprivation therapy). Optimal application of enzalutamide will ultimately require greater insight and attention to mitigating strategies for treatment-associated fatigue, cognitive impairment, and functional decline. This publication will comprehensively analyze the clinical evidence and guiding principles of enzalutamide use in CSPC. We will also provide a critical review of ongoing and future ARSI research focusing on pharmacologic approaches to overcome treatment resistance and strategies to improve treatment-associated functional impairment.